An approach to the evaluation and treatment of Cushing's disease

Expert Review of Anticancer Therapy

Volumn 6, Issue 9 SUPPL., 2006, Pages

  Brown, Rebecca L ^a   Weiss, Roy E ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cushing's disease; Cushing's syndrome; Hypercortisolemia; Transsphenoidal surgery

Indexed keywords

BROMOCRIPTINE; CARBAMAZEPINE; CORTICOTROPIN; CYPROHEPTADINE; DEXAMETHASONE; GLUCOCORTICOID; GONADORELIN AGONIST; GROWTH HORMONE; HYDROCORTISONE; INSULIN; KETOCONAZOLE; LIVER ENZYME; MINERALOCORTICOID; MITOTANE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHENOBARBITAL; PHENYTOIN; PIOGLITAZONE; RIFAMPICIN; ROSIGLITAZONE; SOMATOSTATIN;

ADRENALECTOMY; ALCOHOLISM; BLOOD ANALYSIS; CHILD CARE; COMORBIDITY; CORTICOTROPIN DEFICIENCY; CORTICOTROPIN RELEASE; CUSHING DISEASE; CUSHINGOID SYNDROME; DEPRESSION; DEXAMETHASONE SUPPRESSION TEST; DIAGNOSTIC ACCURACY; DRUG BLOOD LEVEL; DRUG CLEARANCE; ENZYME INDUCTION; FACE DEFORMITY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; GASTROINTESTINAL DISEASE; GROWTH HORMONE DEFICIENCY; HORMONE DETERMINATION; HORMONE SUBSTITUTION; HUMAN; HYPERCORTISOLISM; HYPERTENSION; HYPOPHYSIS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSULIN RESISTANCE; LIVER DYSFUNCTION; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MENTAL DISEASE; MOUSE; MYOPATHY; NELSON SYNDROME; NEPHROLITHIASIS; NEUROLOGIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT MONITORING; PHYSICAL EXAMINATION; POSTOPERATIVE PERIOD; RADIATION DOSE FRACTIONATION; REMISSION; REVIEW; SALIVA ANALYSIS; SENSITIVITY AND SPECIFICITY; SKIN BRUISING; STEREOTAXIC SURGERY; STRIA; SYMPTOM; TRANSSPHENOIDAL SURGERY; TREATMENT FAILURE; URINALYSIS; WASTING SYNDROME;

ANIMALS; CUSHING SYNDROME; HUMANS; PITUITARY ACTH HYPERSECRETION; TREATMENT OUTCOME;

EID: 33750066307     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.9.S37     Document Type: Review

References (73)

1. Boscaro M, Barzon L, Fallo F, Sonino N. Cushing's syndrome. Lancet 357 (9258), 783-791 (2001).
2. Meier CA, Biller BM. Clinical and biochemical evaluation of Cushing's syndrome. Endocrinol. Metab. Clin. N. Am. 26, 741-762 (1997).
3. Etxabe J, Vazquez JA. Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin. Endocrinol. (Oxf). 40(4), 479-484 (2004).
4. Arnaldi G, Angeli A, Atkinson AB, et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J. Clin. Endocrinol. Metab. 88(12), 5593-5602 (2003).
5. Nieman LK: Cushing's Syndrome. In: Endocrinology (Ed. 4, Volume 1). DeGroot LJ, Jameson JL (Eds.), WB Saunders, PA, USA, 1691-1715 (2001).
6. Findling JW, Raff H. Diagnosis and differential diagnosis of Cushing's syndrome. Endocrinol. Metab. Clin. N. Am. 30(3), 729-747 (2001).
7. Contreras LN, Cardoso E, Lozano MP, Pozzo J, Pagano P, Claus-Hermbeg H. Detection of preclinical Cushing's syndrome in overweight type 2 diabetic patients. Medicina (B Aires), 60(3), 326-330 (2000).
8. Trainer PJ, Grossman A. The diagnosis and differential diagnosis of Cushing's syndrome. Clin. Endocrinol. (Oxf). 34, 317-330 (1991).
9. Nieman LK, Cutler Jr GB. The sensitivity of the urine free cortisol measurement as a screeing test for Cushing's syndrome. rogram of the 72nd Annual Meeting of The Endocrine Society, Atlanta, GA, USA, Abstract P-822 (1990).
10. Contreras LN, Hane S, Tyrrell JB. Urinary cortisol in the assessment of pituitary- adrenal function: utility of 24-hour and spot determinations. J. Clin. Endocrinol. Metab. 62(5), 965-969 (1986).
11. Nugent CA, Nichols T, Tyler FH. Diagnosis of Cushing's Syndrome; single dose dexamethasone suppression test. Arch. Intern. Med. 116, 172-176 (1965).
12. Wood PJ, Barth JH, Freedman DB, Perry L, Sheridan B. Evidence for the low dose dexamethasone suppression test to screen for Cushing's syndrome- recommendations for a protocol for biochemistry laboratories. Ann. Clin. Biochem. 34(Pt 3), 222-229 (1997).
13. Meikle AW. Dexamethasone suppression tests: usefulness of simultaneous measurement of plasma cortisol and dexamethasone. Clin. Endocrinol. (Oxf). 16(4), 401-408 (1982).
14. Kapcala LP, Hamilton SM, Meikle AW. Cushing's disease with 'normal suppression' due to decreased dexamethasone clearance. Arch. Intern Med. 144(3), 636-637 (1984).
15. Putignano P, Kaltsas GA, Satta MA, Grossman AB. The effects of anti-convulsant drugs on adrenal function. Horm. Metab. Res. 30(6-7), 389-397 (1998).
16. Findling JW, Raff H. Screening and diagnosis of Cushing's syndrome. Endocrinol. Metab. Clin. N. Am. 34(2), 385-402 (2005).
17. Yaneva M, Mosnier-Pudar H, Dugue MA, Grabar S, Fulla Y, Bertagna X. Midnight salivary cortisol for the initial diagnosis of Cushing's syndrome of various causes. J. Clin. Endocrinol. Metab. 89(7), 3345-3351 (2004).
18. Raff H, Raff JL, Findling JW. Late-night salivary cortisol as a screening test for Cushing's syndrome. J. Clin. Endocrinol. Metab. 83(8), 2681-2686 (1998).
19. Gafni RI, Papanicolaou DA, Nieman LK. Nighttime salivary cortisol measurement as a simple, noninvasive, outpatient screening test for Cushing's syndrome in children and adolescents. J. Pediatr. 137(1), 30-35 (2000).
20. Chen YM, Cintron NM, Whitson PA. Long-term storage of salivary cortisol samples at room temperature. Clin. Chem. 38(2), 304 (1992).
21. Viardot A, Huber P, Puder JJ, Zulewski H, Keller U, Muller B. Reproducibility of nighttime salivary cortisol and its use in the diagnosis of hypercortisolism compared with urinary free cortisol and overnight dexamethasone suppression test. J.. Clin. Endocrinol. Metab. 90(10), 5730-5736 (2005).
22. Liu H, Bravata DM, Cabaccan J, Raff H, Ryzen E. Elevated late-night salivary cortisol levels in elderly male type 2 diabetic veterans. Clin. Endocrinol. (Oxf). 63(6), 642-649 (2005).
23. Cunningham JM, Buxton OM, Weiss RE. Circadian variation in Cushing's disease and pseudo-Cushing states by analysis of F and ACTH pulsatility. J. Endocrinol. Invest. 25(9), 791-799 (2002).
24. Newell-Price J, Trainer P, Perry L, Wass J, Grossman A, Besser M. A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing's syndrome. Clin. Endocrinol. (Oxf). 43(5), 545-550 (1995).
25. Yanovski JA, Cutler GB Jr, Chrousos GP, Nieman LK. Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration. A new test to distinguish Cushing's syndrome from pseudo-Cushing's states. JAMA 269(17), 2232-2238 (1993).
26. Stewart PM: The adrenal cortex. In: Williams Textbook of Endocrinology (ed 10). Larsen PR, Kronenberg HM, Melmed S, et al. (Eds.), WB Saunders, PA, USA, 491-551 (2002).
27. Orth DN. Cushing's syndrome. N. Engl. J. Med. 332(12), 791-803 (1995).
28. Refetoff S, Van Cauter E, Fang VS, Laderman C, Graybeal ML, Landau RL. The effect of dexamethasone on the 24-hour profiles of adrenocorticotropin and cortisol in Cushing's syndrome. J. Clin. Endocrinol. Metab. 60(3), 527-535 (1985).
29. Nieman LK, Oldfield EH, Wesley R, Chrousos GP, Loriaux DL, Cutler GB Jr. A simplified morning ovine corticotropin- releasing hormone stimulation test for the differential diagnosis of adrenocorticotropin- dependent Cushing's syndrome. J. Clin. Endocrinol. Metab. 77(5), 1308-1312 (1993).
30. Invitti C, Pecori Giraldi F, de Martin M, Cavagnini F. Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic- Pituitary-Adrenal Axis. J. Clin. Endocrinol. Metab. 84(2), 440-448 (1999).
31. Mavrakis AN, Tritos NA. Diagnostic and therapeutic approach to pituitary incidentalomas. Endocr Pract. 10(5), 438-444 (2004).
32. Molitch ME, Russell EJ. The pituitary "incidentaloma". Ann. Intern. Med. 112(12), 925-931 (1990).
33. Hall WA, Luciano MG, Doppman JL, Patronas NJ, Oldfield EH. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann. Intern. Med. 120(10), 817-820 (1994).
34. Oldfield EH, Doppman JL, Nieman LK, et al. Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing's syndrome. N. Engl. J. Med. 325(13), 897-905 (1991).
35. Bonelli FS, Huston J 3rd, Carpenter PC, Erickson D, Young WF Jr, Meyer FB. Adrenocorticotropic hormone-dependent Cushing's syndrome: sensitivity and specificity of inferior petrosal sinus sampling. AJNR Am. J. Neuroradiol. 21(4), 690-696 (2006).
36. Teramoto A, Yoshida Y, Sanno N, Nemoto S. Cavernous sinus sampling in patients with adrenocorticotrophic hormone- dependent Cushing's syndrome with emphasis on inter-and intracavernous adrenocorticotrophic hormone gradients. J. Neurosurg. 89(5), 762-768 (1998).
37. Bochicchio D, Losa M, Buchfelder M. Factors influencing the immediate and late outcome of Cushing's disease treated by transsphenoidal surgery: a retrospective study by the European Cushing's Disease Survey Group. J. Clin. Endocrinol. Metab. 80(11), 3114-3120 (1995).
38. Ciric I, Ragin A, Baumgartner C, Pierce D. Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery 40(2), 225-236 (1997).
39. Semple PL, Laws ER Jr. Complications in a contemporary series of patients who underwent transsphenoidal surgery for Cushing's disease. J. Neurosurg. 91(2), 175-179 (1999).
40. Utz AL, Swearingen B, Biller BM. Pituitary surgery and postoperative management in Cushing's disease. Endocrinol. Metab. Clin. N. Am. (2), 459-478 (2005).
41. Esposito F, Dusick JR, Cohan P et al. Clinical review: Early morning cortisol levels as a predictor of remission after transsphenoidal surgery for Cushing's disease. J. Clin. Endocrinol. Metab. 91(1), 7-13 (2006).
42. Blevins LS Jr, Christy JH, Khajavi M, Tindall GT. Outcomes of therapy for Cushing's disease due to adrenocorticotropin-secreting pituitary macroadenomas. J. Clin. Endocrinol. Metab. 83(1), 63-67 (1998).
43. Sonino N, Zielezny M, Fava GA, Fallo F, Boscaro, M. Risk factors and long-term outcome in pituitary-dependent Cushing's disease. J. Clin. Endocrinol. Metab. 81(7), 2647-2652 (1996).
44. Chee GH, Mathias DB, James RA, Kendall-Taylor P. Transsphenoidal pituitary surgery in Cushing's disease: can we predict outcome? Clin. Endocrinol. (Oxf). 54(5), 617-626 (2001).
45. Pieters GF, Hermus AR, Meijer E, Smals AG, Kloppenborg PW. Predictive factors for initial cure and relapse rate after pituitary surgery for Cushing's disease. J. Clin. Endocrinol. Metab. 69(6), 1122-1126 (1989).
46. Rollin GA, Ferreira NP, Junges M, Gross JL, Czepielewski MA. Dynamics of serum cortisol levels after transsphenoidal surgery in a cohort of patients with Cushing's disease. J. Clin. Endocrinol. Metab. 89(3), 1131-1139 (2004).
47. Simmons NE, Alden TD, Thorner MO, Laws ER Jr. Serum cortisol response to transsphenoidal surgery for Cushing disease. J. Neurosurg. 95(1), 1-8 (2001).
48. Chen JC, Amar AP, Choi S, Singer P, Couldwell WT, Weiss MH. Transsphenoidal microsurgical treatment of Cushing disease: postoperative assessment of surgical efficacy by application of an overnight low-dose dexamethasone suppression test. J. Neurosurg. 98(5), 967-973 (2003).
49. Czirjak S, Bezzegh A, Gal A, Racz K. Intra- and postoperative plasma ACTH concentrations in patients with Cushing's disease cured by transsphenoidal pituitary surgery. Acta Neurochir (Wien). 144(10), 971-977 (2002).
50. Nishizawa S, Oki Y, Ohta S, Yokota N, Yokoyama T, Uemura K. What can predict postoperative "endocrinological cure" in Cushing's disease? Neurosurgery 45(2), 239-244 (1999).
51. Shimon I, Ram Z, Cohen ZR, Hadani M. Transsphenoidal surgery for Cushing's disease: endocrinological follow-up monitoring of 82 patients. Neurosurgery 51(1), 57-61 (2002).
52. Ram Z, Nieman LK, Cutler GB Jr, Chrousos GP, Doppman JL, Oldfield EH. Early repeat surgery for persistent Cushing's disease. J. Neurosurg. 80 (1), 37-45 (1994).
53. Friedman RB, Oldfield EH, Nieman LK et al. Repeat transsphenoidal surgery for Cushing's disease. J. Neurosurg. 71(4), 520-527 (1989).
54. Mahmoud-Ahmed AS, Suh JH. Radiation therapy for Cushing's disease: a review. Pituitary 5(3), 175-180 (2002).
55. Vance ML. Pituitary radiotherapy. Endocrinol. Metab. Clin. N. Am. 34(2), 479-487 (2005).
56. Nieman LK. Medical therapy of Cushing's disease. Pituitary. 5(2), 77-82 (2002).
57. Heaney AP, Fernando M, Yong WH, Melmed S. Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat. Med. 8(11), 1281-1287 (2002).
58. Alevizaki M, Philippou G, Zapanti L, Alevizaki CC, Anastasiou E, Mavrikakis M. Significant improvement of recurrent pituitary-dependent Cushing's syndrome after administration of a PPARg agonist. Program of the 86th Annual Meeting of The Endocrine Society. New Orleans, LA, USA, Abstract P2-453 (2004).
59. Ambrosi B, Dall'Asta C, Cannavo S et al. Effects of chronic administration of PPAR- gamma ligand rosiglitazone in Cushing's disease. Eur. J. Endocrinol. 151(2), 173-178 (2004).
60. Cannavo S, Ambrosi B, Chiodini I et al. Baseline and CRH-stimulated ACTH and cortisol levels after administration of the peroxisome proliferator-activated receptor- gamma ligand, rosiglitazone, in Cushing's disease. J. Endocrinol. Invest. 27(5), RC8-11 (2004).
61. Suri D, Weiss RE. Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease. J. Clin. Endocrinol. Metab. 90(3), 1340-1346 (2005).
62. Andreassen M, Kristensen LO. Rosiglitazone for prevention or adjuvant treatment of Nelson's syndrome after bilateral adrenalectomy. Eur. J. Endocrinol. 153(4), 503-505 (2005).
63. Savage MO, Lienhardt A, Lebrethon MC et al. Cushing's disease in childhood: presentation, investigation, treatment and long-term outcome. Horm. Res. 55 Suppl 1, 24-30 (2001).
64. Grua JR, Nelson DH. ACTH-producing pituitary tumors. Endocrinol. Metab. Clin. N. Am. 20(2), 319-362 (1991).
65. Moshang T Jr. Cushing's disease, 70 years later. and the beat goes on. J. Clin. Endocrinol. Metab. 88(1), 31-33 (2003).
66. Joshi SM, Hewitt RJ, Storr HL, et al. Cushing's disease in children and adolescents: 20 years of experience in a single neurosurgical center. Neurosurgery 57(2), 281-5 (2005).
67. Magiakou MA, Mastorakos G, Oldfield EH et al. Cushing's syndrome in children and adolescents. Presentation, diagnosis, and therapy. N. Engl. J. Med. 331(10), 629-636 (1994).
68. Kanter AS, Diallo AO, Jane JA Jr, et al. Single-center experience with pediatric Cushing's disease. J. Neurosurg. 103(5 Suppl.), 413-420 (2005).
69. Leinung MC, Zimmerman D. Cushing's disease in children. Endocrinol. Metab. Clin. N. Am. 23(3), 629-639 (1994).
70. Storr HL, Plowman PN, Carroll PV, et al. Clinical and endocrine responses to pituitary radiotherapy in pediatric Cushing's disease: an effective second-line treatment. J. Clin. Endocrinol. Metab. 88(1), 34-37 (2003).
71. Kamp GA, Mul D, Waelkens JJ, et al. A randomized controlled trial of three years growth hormone and gonadotropin- releasing hormone agonist treatment in children with idiopathic short stature and intrauterine growth retardation. J. Clin. Endocrinol. Metab. 86(7), 2969-2975 (2001).
72. Castro M, Elias PC, Quidute AR, Halah FP, Moreira AC. Out-patient screening for Cushing's syndrome: the sensitivity of the combination of circadian rhythm and overnight dexamethasone suppression salivary cortisol tests. J. Clin. Endocrinol. Metab. 84(3), 872-882 (1999).
73. Castro M, Elias LL, Elias PC, Moreira AC. A dose-response study of salivary cortisol after dexamethasone suppression test in Cushing's disease and its potential use in the differential diagnosis of Cushing's syndrome. Clin. Endocrinol. (Oxf). 59(6), 800-805 (2003).